Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Net Cash Flow (2020 - 2025)

SAB Biotherapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$18.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 119310.81% year-over-year to -$18.5 million; the TTM value through Dec 2025 reached $1.8 million, up 103.83%, while the annual FY2025 figure was $1.8 million, 103.83% up from the prior year.
  • Net Cash Flow reached -$18.5 million in Q4 2025 per SABSW's latest filing, down from $25.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $54.1 million in Q4 2023 to a low of -$42.5 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$83557.6, with a median of -$2.7 million recorded in 2025.
  • Peak YoY movement for Net Cash Flow: skyrocketed 33841.08% in 2021, then crashed 119310.81% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.03% to $54.1 million in 2023, then crashed by 99.97% to $15539.0 in 2024, then plummeted by 119310.81% to -$18.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Net Cash Flow are -$18.5 million (Q4 2025), $25.8 million (Q3 2025), and -$2.1 million (Q2 2025).